Y U So Mad?

The CEO and Founder of Seattle genetics Clay Siegall

Nov
14

The CEO and Founder of Seattle genetics Clay Siegall

A biopharmaceutical company, ultragenyx pharmaceutical.Inc. Which focuses on the production of products for rare and ultra-rare diseases announced the appointment of Mr. clay to the board of directors as from January 30 in the year 2014.Mr siegall and Mr. Fuss are needed by ultragenyx to serve as its independent directors.Dr siegall acknowledged ultragenyxs’growth with its clinical programs and offered to share his expertise for the success of ultragenyx and to importantly help patients with rare and ultra-rare diseases.

Dr. Siegall is the President, Chairman of the board of Directors and also the Chief Executive Officer of Seattle Genetics Inc. which is a biotechnology company that specializes in production and selling of antibody-based therapies for the treatment of cancer. In 1998 Dr. siegall cofounded Seattle genetics, and in 1988 to 1991 he worked for National cancer institute, National Institute of health, from 1991 to 1997 he worked for a pharmaceutical research institute known as Bristol-Myers Squibb. Dr. Siegall also serves as a director in two companies, Mirna Therapeutic and Alder Biopharmaceutical Inc. He got his B.S in zoology in the University of Maryland and a P.H.D in genetics from George Washington University.

Seattle genetics ranks as the largest biotech company in Washington which invests mainly in research and a marketing of new cancer drugs.Siegalls’ ambition is not only in drug development but also to handle all the complexities of international marketing of newer drugs, especially for rare and ultra-rare diseases. Clay Siegall says that he loves making drugs although it’s not easy he keeps pushing on. His strategy is to become a robust entrepreneur and imitates his mentors for his success.

Dr. Siegall built Seattle genetics based on scientific innovation, drug development, and research as well as his passion for helping patients. Under his leadership, the company has developed antibody-drug conjugates (ADCs) for cancer treatment. His motivation to start the company came up from watching his father progress with cancer till his death. He realized that the oncologists had fewer tools and so he wanted to improve the tools. His aim to treat cancer patients and to improve the treatment of cancer for it to be better than it is today.

Dr. Clay has received various awards which include Math and natural sciences, the 2012 Northwest Ernst young entrepreneur of the year and also the 2013 University of Maryland Alumnus of the year for the computer. Siegall has also authored more than 70 publications and holds 15 patents. His work is an excellent motivation to many people.

Leave a Reply